How much cash does Monopar Therapeutics generate?

Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.

Where does Monopar Therapeutics's cash flow data come from?

Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Monopar Therapeutics MNPR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$14.98M-9.2%	-$13.72M+29.4%	-$19.44M-12.3%	-$17.31M-4.5%	-$16.57M-6.3%
Stock-based compensation	$5.18M+7.0%	$4.84M+20.6%	$4.01M+28.9%	$3.11M+43.6%	$2.17M+90.0%
Change in accounts payable	——	——	——	——	$47.06K-90.7%
Change in other current assets	-$330.4K-2,045%	-$15.4K-102%	$723.75K+18.0%	$613.55K+28.1%	$478.95K+3,649%
Net cash from operating activities	-$10.01M+17.9%	-$12.2M-12.7%	-$10.83M-10.4%	-$9.81M+5.8%	-$10.41M-62.6%
Purchases of investments	$126.06M+44.6%	$87.15M+276%	$23.2M+32.8%	$17.48M+7.4%	$16.27M+6.2%
Proceeds from maturities/sales of investments	$57.35M+142%	$23.7M+212%	$7.6M+52.4%	$4.99M+92.8%	$2.59M+162%
Net cash from investing activities	-$68.71M-8.3%	-$63.45M-307%	-$15.6M-24.9%	-$12.49M+8.7%	-$13.68M+4.6%
Proceeds from issuance of common stock	$0—	$0-100%	$1.01M—	——	——
Taxes paid for net share settlement	$1.2M+6.1%	$1.13M+25.6%	$901.19K+68.1%	$536.16K+139%	$224.61K+116%
Net cash from financing activities	$91.87M-0.1%	$91.96M-37.9%	$148.1M—	——	——
Effect of exchange rate changes on cash	$65.69K-32.5%	$97.27K—	——	——	——
Net increase (decrease) in cash	——	——	$121.66M+264%	$33.38M+4.6%	$31.9M-17.2%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	$126.27K+1,301%
Increase (Decrease) in Other Current Assets	-$330.4K-2,045%	-$15.4K-102%	$723.75K+18.0%	$613.55K+28.1%	$478.95K+3,649%
Satisfaction of management and incentive fees in stock	——	$0-100%	$1.14M-50.0%	$2.28M-33.3%	$3.41M-25.0%
Payments to Acquire Short-Term Investments	$126.06M+44.6%	$87.15M+276%	$23.2M+32.8%	$17.48M+7.4%	$16.27M+6.2%
Proceeds from maturities of short-term investments	$57.35M+142%	$23.7M+212%	$7.6M+52.4%	$4.99M+92.8%	$2.59M+162%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$65.69K-32.5%	$97.27K—	——	——	——
Increase Decrease In Inprocess Research And Development Accrued Expenses	——	——	——	——	$0+100%
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities	$8.61K-8.7%	$9.43K—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	$573.25K+96.7%	$291.43K+129%	$127.34K0.0%	$127.34K—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?: Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?: Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.